RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

Cutting Edge


Issue 43
Beyond survival:  what should new cancer drugs have to prove and how?
Issue 42
International biobanking regulations:  the promise and the pitfalls
Issue 41
Reading the signs:  the role of genomic signatures in guiding treatment decisions
Issue 40
Promoting genetic literacy: cancer control in the BRCA era
Issue 39
Therapeutic cancer vaccines: there's a new kid on the block
Issue 38
Charged particle therapy
Issue 37
Grapefruit juice and St John's Wort are just the tip of the iceberg
Issue 36
Who's who in the world of personalised cancer treatments
Issue 35
MRI for breast cancer: who benefits, who is harmed?
Issue 34
Keyhole surgery

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR16 - Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists (based on a review article of Critical Reviews in Oncology Hematology)

GR182 - Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

GR183 - The current management of low-grade glioma in childhood

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.